Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Goodwill & Intangibles (2016 - 2025)

Ani Pharmaceuticals' Goodwill & Intangibles history spans 14 years, with the latest figure at $15.8 million for Q2 2025.

  • For Q2 2025, Goodwill & Intangibles changed N/A year-over-year to $15.8 million; the TTM value through Jun 2025 reached $15.8 million, changed N/A, while the annual FY2024 figure was $601.8 million, N/A changed from the prior year.
  • Goodwill & Intangibles for Q2 2025 was $15.8 million at Ani Pharmaceuticals, down from $601.8 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $601.8 million in Q4 2024 and bottomed at $3.6 million in Q1 2021.
  • The 5-year median for Goodwill & Intangibles is $149.8 million (2023), against an average of $197.2 million.
  • The largest annual shift saw Goodwill & Intangibles crashed 98.37% in 2021 before it skyrocketed 8552.54% in 2022.
  • A 5-year view of Goodwill & Intangibles shows it stood at $528.4 million in 2021, then crashed by 47.04% to $279.9 million in 2022, then plummeted by 88.38% to $32.5 million in 2023, then soared by 1750.57% to $601.8 million in 2024, then plummeted by 97.37% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Goodwill & Intangibles are $15.8 million (Q2 2025), $601.8 million (Q4 2024), and $32.5 million (Q2 2023).